Collegium Pharmaceutical Inc (COLL)
33.46
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 13:15
Collegium Pharmaceutical Net Income (Quarterly): 19.61M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 19.61M |
| March 31, 2024 | 27.71M |
| December 31, 2023 | 31.94M |
| September 30, 2023 | 20.63M |
| June 30, 2023 | 13.01M |
| March 31, 2023 | -17.43M |
| December 31, 2022 | -7.199M |
| September 30, 2022 | 0.457M |
| June 30, 2022 | -5.191M |
| March 31, 2022 | -13.07M |
| December 31, 2021 | -25.03M |
| September 30, 2021 | 8.046M |
| June 30, 2021 | 72.84M |
| March 31, 2021 | 15.66M |
| December 31, 2020 | 6.958M |
| September 30, 2020 | 11.29M |
| June 30, 2020 | 8.058M |
| March 31, 2020 | 0.45M |
| December 31, 2019 | -2.201M |
| September 30, 2019 | -6.109M |
| June 30, 2019 | -4.712M |
| Date | Value |
|---|---|
| March 31, 2019 | -9.70M |
| December 31, 2018 | 9.086M |
| September 30, 2018 | -16.50M |
| June 30, 2018 | -13.06M |
| March 31, 2018 | -18.65M |
| December 31, 2017 | -17.40M |
| September 30, 2017 | -13.26M |
| June 30, 2017 | -21.12M |
| March 31, 2017 | -23.08M |
| December 31, 2016 | -27.56M |
| September 30, 2016 | -26.44M |
| June 30, 2016 | -24.52M |
| March 31, 2016 | -15.65M |
| December 31, 2015 | -9.525M |
| September 30, 2015 | -9.362M |
| June 30, 2015 | -4.674M |
| March 31, 2015 | -3.694M |
| December 31, 2014 | -3.469M |
| September 30, 2014 | -6.556M |
| June 30, 2014 | -4.117M |
| March 31, 2014 | -3.773M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-25.03M
Minimum
Dec 2021
72.84M
Maximum
Jun 2021
8.765M
Average
8.046M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| Rigel Pharmaceuticals Inc | -1.03M |
| Esperion Therapeutics Inc | -61.92M |
| Context Therapeutics Inc | -2.254M |
| NovaBay Pharmaceuticals Inc | -1.585M |
| Palatin Technologies Inc | -8.250M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 145.28M |
| Total Expenses (Quarterly) | 97.80M |
| EPS Diluted (Quarterly) | 0.52 |
| Enterprise Value | 1.359B |
| Gross Profit Margin (Quarterly) | 62.51% |
| Profit Margin (Quarterly) | 13.50% |
| Earnings Yield | 7.74% |
| Operating Earnings Yield | 13.12% |
| Normalized Earnings Yield | 8.099 |